Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is a fast-growing biopharmaceutical technology development company that specialises in the production of microbial recombinant proteins and the development of advanced bioprocessing technologies. As a supplier to the pharmaceutical industry, Paras focuses on the design, development, and optimisation of manufacturing technologies for biologics and biosimilars, utilising proprietary platforms that enhance expression and efficiency. The company's commitment to innovation is evident in its extensive intellectual property portfolio and proprietary technologies.

Services include:
- Contract development & microbial biologics manufacturing (CDMO)
- Development of recombinant expression systems and process technologies for biologics and biosimilars
- Production of recombinant IL1-RA / Anakinra (Kineret® Biosimilar)
- Production of recombinant Romiplostim (Nplate® Biosimilar)
- Manufacturing of recombinant bioprocess enzymes, including Enterokinase & TEV Protease
- Proprietary technologies such as Diabrid® Technology, NobleCleav® Technologies, Biomultifold® Technology, and Cytoplasmic Protein Folding Technologies
- cGMP compliant facility for the production of biologics APIs, including analog insulins, osteoporosis (Teriparatide), and oncology products
- Advanced biotechnologies for the production of biologics

Paras Biopharmaceuticals Finland Oy is dedicated to advancing the biopharmaceutical landscape and continues to expand its portfolio of innovative solutions.